Navigation Links
Martek Announces Fourth Quarter and FY 2007 Financial Results
Date:12/12/2007

6 35,290

Changes in operating assets and

liabilities, net (17,859) (14,606)

Net cash provided by operating activities 45,860 35,622

Investing activities:

Expenditures for property, plant and

equipment (8,279) (10,902)

Proceeds from sale of fluorescent detection

products business 900 -

Repurchase of sale-leaseback equipment (3,910) (6,877)

Capitalization of intangible assets (6,010) (6,862)

Net cash used in investing activities (17,299) (24,641)

Financing activities:

Repayments of notes payable and other

long-term obligations, net (1,013) (3,009)

Repayments under revolving credit

facility, net (36,000) (19,000)

Proceeds from stock option exercises

and other, net 3,272 4,509

Net cash used in financing activities (33,741) (17,500)

Net change in cash, cash equivalents and

short-term investments (5,180) (6,519)

Cash, cash equivalents and short-term

investments, beginning of period 26,828 33,347

Cash, cash equivalents and short-term

investments, end of period $21,648 $26,828

CONTACT

Kyle Stults

Investor Relations

(410) 740-0081

kstults@martek.com


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Martek to Announce Third Quarter 2007 Results on September 5, 2007
2. Martek to Present at Upcoming UBS Conference
3. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
4. Martek Announces Settlement of OmegaTech Milestone Litigation
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
7. Martek to Present at Upcoming ThinkEquity Partners Conference
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 Mathematic studies at the Program ... and funded by the Jeffrey Epstein VI Foundation , ... be visually identified for elimination. These aggressive cells are the ... shows a topological map of what to look for when ... for while tumor cells can be extracted from biopsy, it,s ...
(Date:8/21/2014)... Ontotext S4 , The Self Service Semantic ... Now the same enterprise hardened text mining, Linked Data ... is available to start-ups and mid-size businesses at a ... do not have resources to evaluate and prototype enterprise ... there is no need for on premise hardware provisioning ...
(Date:8/20/2014)... to biotechnology firms has revealed early bottlenecks on ... the researchers suggest that better communication of basic ... to faster commercialization down the road. , Biopharmaceutical ... university laboratories and licensed to biotechnology firms. Bottlenecks ... a high failure rate. But a new study ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014  Decision Resources Group finds ... , Russia , India ... $1.6 billion in 2013, roughly equal to the size of ... however, the BRIC market will experience much faster growth as a ... aging population. Other key findings from Decision Resources Group,s ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... Calif., March 9 Cord Blood America, Inc. (OTC ... preservation company ( http://www.cordblood-america.com ) focused on bringing ... nationwide and internationally, said today that it believes the ... on Federal funding of stem cell research is a ...
... YORK, March 9 Cynvec LLC, a privately held ... harness the apoptotic ability of the sindbis viral vector, ... Officer, will present at the Cowen and Company 29th ... 16, 2009 at 4:00 p.m. ET. About ...
... CAMBRIDGE, Mass., March 9 Merrimack Pharmaceuticals, Inc., a ... development of novel treatments for cancer and autoimmune disease, ... to Senior Vice President and Chief Scientific Officer and ... Business Development. "Ulrik and Tad have both played ...
Cached Biology Technology:Cord Blood America Sees Significant Positives in President Obama's Lifting of Stem Cell Funding Restrictions 2Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development 2
(Date:8/21/2014)... feeding tube connectors, designed by an international standards process, ... , According to an invited review published in the ... ( NCP ), the official journal of the American ... connectors will greatly reduce the occurrence of misconnection that ... Small-bore connectors, which are used to join medical devices, ...
(Date:8/21/2014)... successfully replicated one of the crucial steps in photosynthesis, ... which could manufacture hydrogen as a fuel. , "Water ... exciting prospect to use them to create hydrogen, and ... from the ARC Centre of Excellence for Translational Photosynthesis ... offers potential as a zero-carbon replacement for petroleum products, ...
(Date:8/21/2014)... in severe abdominal pain, vomiting and systemic inflammation. Every ... with the disease resulting in 1000 deaths. There is ... fluid and nutritional support. , Dr Jason Bruce, ... research, said "The major causes of pancreatitis include bile ... combined with a high fat diet. In fact, the ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Water and sunlight the formula for sustainable fuel 2Insulin offers new hope for the treatment of acute pancreatitis 2
... NY, October 13, 2010Parents of children with undiagnosed learning ... of psychological and social challenges, which are explored in ... and Molecular Biomarkers , a peer-reviewed journal published by ... is available free online ahead of print at ...
... solved an important mystery about why an arsenic compound, ... an effective therapeutic agent against disease and infections. According ... of Genetics ( http://www.genetics.org ) scientists from ... common water contaminant in many parts of the world, ...
... new study conducted by a researcher at Ben-Gurion University ... Social Policy Studies in Israel reports that Israeli,s have ... residents of other OECD (Organization for Economic Cooperation and ... from 2005, the average American life expectancy is now ...
Cached Biology News:Unexplained childhood disorders 2Scientists solve mystery of arsenic compound 2Life expectancy higher in Israel than in US, according to Ben-Gurion U. researcher 2
... materials for 1,464 array sample elements. , , ,Includes: ... , Blocker BSA in PBS (10X): 50 ml ... Phosphate Buffered Saline: 8 packs , 10% Tween-20: ... Luminol Enhancer: 2 x 25 ml , SuperSignal West ...
... Counter Analyser counts cells based on specific ... only cells, so that other non cellular ... through a 250 m square quartz cuvette ... which is used as a counting signal ...
... Accurate Results Laser Capture Microdissection (LCM) ... and accuracy of molecular assays by starting ... multi-cellular structures isolated from whole tissue or ... in 1996 at the National Institutes of ...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
Biology Products: